Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
0.1%Capital Expenditures to Operating Cash Flow
VS
Market
Sector
Industry
History
$ 14.26Close
$ 8.21 - $ 14.6 52-Week Range
Ticker Information
Ticker
TBPHCompany Name
THERAVANCE BIOPHARMA INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQTHERAVANCE BIOPHARMA INC - Capital Expenditures to Operating Cash Flow Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
TBPH - CapEx/OCF Historical data
| Date | Capital Expenditure | Capital Expenditures to Operating Cash Flow | Net Cash Flow - Operations |
|---|---|---|---|
| 6/30/2025 | $ 239K | 0.1% | $ 245.01M |
| 3/31/2025 | $ 241K | 0.74% | $ 32.53M |
| 12/31/2024 | $ 332K | 0% | $ -11.54M |
| 9/30/2024 | $ 819K | 0% | $ -11.49M |
| 6/30/2024 | $ 825K | 0% | $ -8.78M |
| 3/31/2024 | $ 338K | 0% | $ -16.8M |
| 12/31/2023 | $ 975K | 0% | $ -27M |
| 9/30/2023 | $ 564K | 0% | $ -150.2M |
| 6/30/2023 | $ 486K | 0% | $ -169.85M |
| 3/31/2023 | $ 1.03M | 0% | $ -172.14M |
Key Performance Insights, Last 5 Years
- THERAVANCE BIOPHARMA INC's latest trailing twelve months (TTM) CapEx/OCF stands at 0%.
- Over the past 5 years, THERAVANCE BIOPHARMA INC's average CapEx/OCF has been 0.42%.
- The median CapEx/OCF for THERAVANCE BIOPHARMA INC during this period was 0.42%
- THERAVANCE BIOPHARMA INC reached its highest CapEx/OCF over the past 5 years at 0.74%.
- The lowest CapEx/OCF recorded by THERAVANCE BIOPHARMA INC in the same timeframe 0.1%
THERAVANCE BIOPHARMA INC's CapEx/OCF vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
CapEx/OCF Benchmarks
Similar metrics to CF - Operations:
- Free Cash Flow - [Calculation] Free Cash Flow is a metric that measures the cash that remains after a company pays its operating expenses [OpEx] and capital expenditures [CapEx]. It can be calculated as Net Cash Flow from Operations [NCFO] minus capital expenditures.
- Capital Expenditures Coverage - [Calculation] The Capital Expenditure Ratio, or capex coverage, describes the ability of a business to generate enough cash from day-to-day operations to cover capital expenditures. It is calculated by dividing the cash flow from operations [NCFO] by its capital expenditures [CapEx].
- Capital Expenditures Margin - [Calculation] The CapEx Margin, also named Capex to Revenue Ratio, measures how much of a company’s revenue is reinvested into productive [Assets]. It is capital expenditures [CapEx] divided by [Revenue].
- Free Cash Flow to Operating Cash Flow - [Calculation] The Free Cash Flow to Cash Flow from Operations ratio, describes how much of a company’s operating cash flow [NCFO] is free to be invested after capital expenditures [CapEx].
- Capital Expenditure - [Cash Flow Statement] CapEX, also know as capital expenditures, is a component of investing cash flow [NCFI] that refers to funds that are used to acquire, improve or maintain long-term assets [AssestsNC] of the company. Capital expense may include the purchase of new equipment, machinery, buildings or warehouses, furniture, software or intangibles such as intellectual property.
Definition of Capital Expenditures to Operating Cash Flow
[Calculation] The CapEx to Operating Cash Flow ratio, measures how much of a company’s operating cash flow is reinvested into productive [Assets]. It is capital expenditures [CapEx] divided by net operating cash flow [NCFO].CapEx / CF - Operations
(=) CapEx/OCF CapEx/OCF for THERAVANCE BIOPHARMA INC is calculated as follows: CapEx [ $ 6.64M ] / CF - Operations [ $ -249.83M ]
(=) CapEx/OCF [ 0% ] TBPH - Capital Expenditures to Operating Cash Flow, Last 5 years
0.1%
Minimum
Jun 30, 2025
0.74%
Maximum
Mar 31, 2025
0.42%
Average
0.42%
Median
CapEx/OCF Benchmark AnalysisMarket
The chart above depicts the distribution of CapEx/OCF for companies in the Total Stock Market. The average CapEx/OCF of the companies is 31.82% with a standard deviation of 29.54%.
The following table provides additional summary stats:
CapEx/OCF in the Market:
| filtered constituents | 2.35K |
|---|---|
| min | 0.01% |
| max | 128% |
| average | 31.82% |
| median | 22.41% |
| std | 29.54% |